Guest: Everett E. Vokes, MD

In this Grand Rounds recorded live at ASCO, Dr. Vokes introduces the concept of T-cell blockade and Checkpoint Inhibition as rationale for considering use of anti-PD-1 anti-CTLA-4 agents in the management of non-small cell lung cancer (NSCLC). Also discussed will be data reflective of the use of tumor biomarkers when selecting treatment strategies for patients with NSCLC, specifically those with elevated expression of PD-L1.